Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Viread

Viread 33 mg/g granules · Abschnitt 4.5 · PDF-Seite 172

Didanosine Co-administration of tenofovir disoproxil and didanosine is not recommended (see section 4.4 and Table 2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 72bea5e33ac328c3951e71246b69bf4c2114ece9a65a2b7afb81c1028c18f0c5 · Zeichen 499–616 im Abschnitt

Wechselwirkungen · Viread

Viread 33 mg/g granules · Abschnitt 4.5 · PDF-Seite 173

HOS-110864 · Präparat HOS-093385

Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with 245 mg (dose in mg) Cmax, Cmin tenofovir disoproxil ANTI-INFECTIVES Antiretrovirals Protease inhibitors Atazanavir/Ritonavir Atazanavir: No dose adjustment is (300 q.d./100 q.d.) AUC: ↓ 25% recommended. The increased Cmax: ↓ 28% exposure of tenofovir could Cmin: ↓ 26% potentiate tenofovir-associated Tenofovir: adverse events, including renal AUC: ↑ 37% disorders. Renal function should Cmax: ↑ 34% be closely monitored Cmin: ↑ 29% (see section 4.4). Lopinavir/Ritonavir Lopinavir/ritonavir: No dose adjustment is (400 b.i.d./100 b.i.d.) No significant effect on recommended. The increased lopinavir/ritonavir PK exposure of tenofovir could parameters. potentiate tenofovir-associated Tenofovir: adverse events, including renal AUC: ↑ 32% disorders. Renal function should Cmax: ↔ be closely monitored Cmin: ↑ 51% (see section 4.4). Darunavir/Ritonavir Darunavir: No dose adjustment is (300/100 b.i.d.) No significant effect on recommended. The increased darunavir/ritonavir PK exposure of tenofovir could parameters. potentiate tenofovir-associated Tenofovir: adverse events, including renal AUC: ↑ 22% disorders. Renal function should Cmin: ↑ 37% be closely monitored (see section 4.4). NRTIs Didanosine Co-administration of tenofovir Co-administration of tenofovir disoproxil and didanosine results disoproxil and didanosine is not in a 40-60% increase in systemic recommended (see section 4.4). exposure to didanosine. Increased systemic exposure to didanosine may increase didanosine related adverse reactions. Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported. Co-administration of tenofovir disoproxil and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine. A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) didanosine (HOS-085836) darunavir (HOS-086181) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 2da8a9413a0cdf6c2adfbb5e8a3514645ef92df343ae795985c6e470290e6c16 · Zeichen 1809–6983 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11

HOS-112069 · Präparat HOS-093615

The mechanism of interaction between atazanavir and ritonavir is CYP3A4 inhibition. Indinavir Indinavir is associated with indirect Co-administration of REYATAZ unconjugated hyperbilirubinaemia due to and indinavir is not recommended inhibition of UGT. (see section 4.4). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) Lamivudine 150 mg twice daily No significant effect on lamivudine and Based on these data and because + zidovudine 300 mg twice daily zidovudine concentrations was observed. ritonavir is not expected to have a (atazanavir 400 mg once daily) significant impact on the pharmacokinetics of NRTIs, the co- administration of these medicinal products and REYATAZ is not expected to significantly alter the exposure of the co-administered medicinal products. Abacavir The co-administration of abacavir and REYATAZ is not expected to significantly alter the exposure of abacavir. Didanosine (buffered tablets) Atazanavir, simultaneous administration Didanosine should be taken at the 200 mg/stavudine 40 mg, both with ddI+d4T (fasted) fasted state 2 hours after single dose Atazanavir AUC: ↓87% (↓92% ↓79%) REYATAZ taken with food. The (atazanavir 400 mg single dose) Atazanavir Cmax: ↓89% (↓94% ↓82%) co-administration of stavudine with Atazanavir Cmin: ↓84% (↓90% ↓73%) REYATAZ is not expected to significantly alter the exposure of Atazanavir, dosed 1 hr after ddI+d4T stavudine. (fasted) Atazanavir AUC: ↔3% (↓36% ↑67%) Atazanavir Cmax: ↑12% (↓33% ↑18%) Atazanavir Cmin: ↔3% (↓39% ↑73%)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) stavudine (HOS-088080) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) ritonavir (HOS-084521) abacavir (HOS-088077)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e16bb7b3c75a72e29e2846a95fde7bf075f1035a1823dc0170957041762fa37d · Zeichen 9816–12649 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11

HOS-112070 · Präparat HOS-093615

Atazanavir concentrations were greatly decreased when co-administered with didanosine (buffered tablets) and stavudine. The mechanism of interaction is a reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): stavudine (HOS-088080) didanosine (HOS-085836)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 2677cf4b3780ed4bd5e95e25fc73f1edd1208f89e632b701e072eefaf27adca5 · Zeichen 12688–13227 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11

HOS-112071 · Präparat HOS-093615

No significant effect on didanosine and stavudine concentrations was observed.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): stavudine (HOS-088080) didanosine (HOS-085836)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 49a852b644cd0d136d49987d6e696b9604e7edaf1516396807a1f6ca0caf4de2 · Zeichen 13266–13381 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11–12

HOS-112072 · Präparat HOS-093615

11 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration Didanosine (enteric coated Didanosine (with food) capsules) 400 mg single dose Didanosine AUC: ↓34% (↓41% ↓27%) (atazanavir 300 mg once daily Didanosine Cmax: ↓38% (↓48% ↓26%) with ritonavir 100 mg once daily) Didanosine Cmin: ↑25% (↓8% ↑69%)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 0cb6f3bfd4c6a2a0ed65765dbb5c5e1dec1d95189d1adba44aadca039bf6a9d4 · Zeichen 13442–13920 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12

HOS-112073 · Präparat HOS-093615

No significant effect on atazanavir concentrations was observed when administered with enteric-coated didanosine, but administration with food decreased didanosine concentrations. Tenofovir disoproxil fumarate Atazanavir AUC: ↓22% (↓35% ↓6%) * When co-administered with 300 mg once daily Atazanavir Cmax: ↓16% (↓30% ↔0%) * tenofovir disoproxil fumarate, it is (atazanavir 300 mg once daily Atazanavir Cmin: ↓23% (↓43% ↑2%) * recommended that REYATAZ with ritonavir 100 mg once daily) 300 mg be given with ritonavir * In a combined analysis from several 100 mg and tenofovir disoproxil 300 mg tenofovir disoproxil clinical studies, atazanavir/ritonavir fumarate 300 mg (all as a single fumarate is equivalent to 245 mg 300/100 mg co-administered with dose with food). tenofovir disoproxil. tenofovir disoproxil fumarate 300 mg (n = 39) was compared to Studies conducted in HIV- atazanavir/ritonavir 300/100 mg (n = 33). infected patients The efficacy of REYATAZ/ritonavir in combination with tenofovir disoproxil fumarate in treatment-experienced patients has been demonstrated in clinical study 045 and in treatment naïve patients in clinical study 138 (see sections 4.8 and 5.1). The mechanism of interaction between atazanavir and tenofovir disoproxil fumarate is unknown. Tenofovir disoproxil fumarate Tenofovir disoproxil fumarate AUC: ↑37% Patients should be closely 300 mg once daily (↑30% ↑45%) monitored for tenofovir disoproxil (atazanavir 300 mg once daily Tenofovir disoproxil fumarate Cmax: ↑34% fumarate-associated adverse with ritonavir 100 mg once daily) (↑20% ↑51%) reactions, including renal disorders. Tenofovir disoproxil fumarate Cmin: ↑29% 300 mg tenofovir disoproxil (↑21% ↑36%) fumarate is equivalent to 245 mg tenofovir disoproxil. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg once daily Atazanavir (pm): all administered with Co-administration of efavirenz and (atazanavir 400 mg once daily food REYATAZ is not recommended with ritonavir 100 mg once daily) Atazanavir AUC: ↔0%(↓9% ↑10%)* (see section 4.4). Atazanavir Cmax: ↑17%(↑8% ↑27%)* Atazanavir Cmin: ↓42%(↓51% ↓31%)* Efavirenz 600 mg once daily Atazanavir (pm): all administered with (atazanavir 400 mg once daily food with ritonavir 200 mg once daily) Atazanavir AUC: ↔6% (↓10% ↑26%)*/** Atazanavir Cmax: ↔9% (↓5% ↑26%)*/** Atazanavir Cmin: ↔12% (↓16% ↑49%)*/** *When compared to REYATAZ 300 mg/ritonavir 100 mg once daily in the evening without efavirenz. This decrease in atazanavir Cmin might negatively impact the efficacy of atazanavir. The mechanism of efavirenz/atazanavir interaction is CYP3A4 induction.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) didanosine (HOS-085836) fumarate (HOS-108845) efavirenz (HOS-087947) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 7bb7bde08aba3c87ff8884ed201528362530687526da177fc8f79451b0f7859f · Zeichen 13958–17928 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 46–47

HOS-112170 · Präparat HOS-093615

46 Medicinal products by Interaction Recommendations therapeutic area concerning co-administration Didanosine (buffered tablets) Atazanavir, simultaneous administration Didanosine should be taken at 200 mg/stavudine 40 mg, both with ddI+d4T (fasted) the fasted state 2 hours after single dose Atazanavir AUC: ↓87% (↓92% ↓79%) REYATAZ taken with food. (atazanavir 400 mg single Atazanavir Cmax: ↓89% (↓94% ↓82%) The co-administration of dose) Atazanavir Cmin: ↓84% (↓90% ↓73%) stavudine with REYATAZ is not expected to significantly Atazanavir, dosed 1 hr after ddI+d4T alter the exposure of stavudine. (fasted) Atazanavir AUC: ↔3% (↓36% ↑67%) Atazanavir Cmax: ↑12% (↓33% ↑18%) Atazanavir Cmin: ↔3% (↓39% ↑73%)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): stavudine (HOS-088080) didanosine (HOS-085836)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage cf00ba3cf0ef9ca5a99a8f1d2aed41200a0098d707d9b939153d792dbf56a62b · Zeichen 12026–13230 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 47

HOS-112171 · Präparat HOS-093615

Atazanavir concentrations were greatly decreased when co-administered with didanosine (buffered tablets) and stavudine. The mechanism of interaction is a reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): stavudine (HOS-088080) didanosine (HOS-085836)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 829d65dbef7f81f64f28357dc9f27b31f3c369952c6c738ad8969c2fb82fa2c5 · Zeichen 13264–13736 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 47

HOS-112172 · Präparat HOS-093615

No significant effect on didanosine and stavudine concentrations was observed. Didanosine (enteric coated Didanosine (with food) capsules) 400 mg single dose Didanosine AUC: ↓34% (↓41% ↓27%) (atazanavir 300 mg once daily Didanosine Cmax: ↓38% (↓48% ↓26%) with ritonavir 100 mg once Didanosine Cmin: ↑25% (↓8% ↑69%) daily) No significant effect on atazanavir concentrations was observed when administered with enteric-coated didanosine, but administration with food decreased didanosine concentrations. Tenofovir disoproxil Atazanavir AUC: ↓22% (↓35% ↓6%)* When co-administered with fumarate 300 mg once daily Atazanavir Cmax: ↓16% (↓30% ↔0%)* tenofovir disoproxil fumarate, (atazanavir 300 mg once daily Atazanavir Cmin: ↓23% (↓43% ↑2%)* it is recommended that with ritonavir 100 mg once REYATAZ 300 mg be given daily) *In a combined analysis from several with ritonavir 100 mg and clinical studies, atazanavir/ritonavir tenofovir disoproxil fumarate 300 mg tenofovir disoproxil 300/100 mg co-administered with tenofovir 300 mg (all as a single dose fumarate is equivalent to disoproxil fumarate 300 mg (n = 39) was with food). 245 mg tenofovir disoproxil. compared to atazanavir/ritonavir 300/100 mg (n = 33). Studies conducted in HIV- infected patients The efficacy of REYATAZ/ritonavir in combination with tenofovir disoproxil fumarate in treatment-experienced patients has been demonstrated in clinical study 045 and in treatment naive patients in clinical study 138 (see sections 4.8 and 5.1). The mechanism of interaction between atazanavir and tenofovir disoproxil fumarate is unknown.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) stavudine (HOS-088080) tenofovir disoproxil (HOS-108843) didanosine (HOS-085836) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 85dd1351f7e7583a5f13a723d7100c44d38f3263361d690ef402b7958692fcf6 · Zeichen 13770–16089 im Abschnitt

Wechselwirkungen · Kivexa

Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-113477 · Präparat HOS-093937

Drugs by Therapeutic Area Interaction Recommendation concerning Geometric mean change (%) co-administration (Possible mechanism) ANTIRETROVIRAL MEDICINAL PRODUCTS Didanosine /Abacavir Interaction not studied. No dosage adjustment Didanosine/Lamivudine Interaction not studied. necessary. Zidovudine/Abacavir Interaction not studied Zidovudine/Lamivudine Lamivudine: AUC  Zidovudine 300 mg single dose Zidovudine : AUC  Lamivudine 150 mg single dose Emtricitabine/Lamivudine Due to similarities, Kivexa should not be administered concomitantly with other cytidine analogues, such as emtricitabine. ANTI-INFECTIVE PRODUCTS Trimethoprim/sulfamethoxazole Interaction not studied. No Kivexa dosage adjustment (Co-trimoxazole)/Abacavir necessary. Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% (Co-trimoxazole)/Lamivudine When concomitant (160 mg/800 mg once daily for Trimethoprim: AUC  administration with 5 days/300 mg single dose) Sulfamethoxazole: AUC  co-trimoxazole is warranted,

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) didanosine (HOS-085836) zidovudine (HOS-085837) emtricitabine (HOS-085840)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 3b23f2886f7d80d744304e64283fcb23c64e14afd5a52f5e8622a5373e4f7cc1 · Zeichen 1544–3217 im Abschnitt

Wechselwirkungen · Truvada

Truvada 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-113714 · Präparat HOS-093961

Didanosine: The co-administration of Truvada and didanosine is not recommended (see section 4.4 and Table 2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T18:10:00Z · SHA-256 c649f98085684f03838a5e69a1a4e7a871850d61dfdc001f745e6b31db212087 · Passage b26255d88eeb9199c631165d0666fb4095bd19853a2c50674c906860dc23b510 · Zeichen 1048–1157 im Abschnitt

Wechselwirkungen · Truvada

Truvada 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11

HOS-113721 · Präparat HOS-093961

10 Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with Truvada Cmax, Cmin with 90% confidence (emtricitabine 200 mg, tenofovir intervals if available disoproxil 245 mg) (mechanism) Lopinavir/Ritonavir/Tenofovir Lopinavir/Ritonavir: No dose adjustment is disoproxil AUC: ↔ recommended. The increased (400 mg b.i.d./100 mg b.i.d/245 mg Cmax: ↔ exposure of tenofovir could q.d.) Cmin: ↔ potentiate tenofovir associated adverse events, including renal Tenofovir: disorders. Renal function should AUC: ↑ 32% (↑ 25 to ↑ 38) be closely monitored (see Cmax: ↔ section 4.4). Cmin: ↑ 51% (↑ 37 to ↑ 66) Lopinavir/Ritonavir/Emtricitabine Interaction not studied. NRTIs Didanosine/Tenofovir disoproxil Co-administration of tenofovir Co-administration of Truvada and disoproxil and didanosine results didanosine is not recommended in a 40-60% increase in systemic (see section 4.4). exposure to didanosine. Didanosine/Emtricitabine Interaction not studied. Increased systemic exposure to didanosine may increase didanosine-related adverse reactions. Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported. Co-administration of tenofovir disoproxil and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine. A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection. Lamivudine/Tenofovir disoproxil Lamivudine: Lamivudine and Truvada should AUC: ↓ 3% (↓ 8% to ↑ 15) not be administered concomitantly Cmax: ↓ 24% (↓ 44 to ↓ 12) (see section 4.4). Cmin: NC

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) lamivudine (HOS-085829) didanosine (HOS-085836) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-02-29T18:10:00Z · SHA-256 c649f98085684f03838a5e69a1a4e7a871850d61dfdc001f745e6b31db212087 · Passage 34d1ca2844dfd09b2441ac7d077d375ca89f87b4676eb7242bcdfd51de9e1bf1 · Zeichen 4435–8759 im Abschnitt

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 10

HOS-114811 · Präparat HOS-094169

Abacavir 300 mg BID Abacavir Cmax ↓ 46% The concomitant use of Aptivus, (TPV/r 750/100 mg BID) Abacavir AUC ↓ 36% co-administered with low dose ritonavir, with abacavir is not The clinical relevance of this recommended unless there are no reduction has not been other available NRTIs suitable for established, but may decrease patient management. In such the efficacy of abacavir. cases no dosage adjustment of abacavir can be recommended Mechanism unknown. (see section 4.4). Didanosine 200 mg BID, Didanosine Cmax ↓ 43% Dosing of enteric-coated ≥ 60 kg (TPV/r 250/200 mg Didanosine AUC ↓ 33% didanosine and Aptivus soft BID) - 125 mg BID, < 60 kg capsules, co-administered with (TPV/r 750/100 mg BID) low dose ritonavir, should be Didanosine Cmax ↓ 24% separated by at least 2 hours to Didanosine AUC ↔ avoid formulation incompatibility. The clinical relevance of this reduction in didanosine concentrations has not been established.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836) ritonavir (HOS-084521) abacavir (HOS-088077)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage dc467715c0253d376232fd8621af28714f574b47724b843a086e90ab970bca73 · Zeichen 4554–6273 im Abschnitt

Wechselwirkungen · Siklos

Siklos 100 mg film-coated tablet. Siklos 1 000 mg film-coated tablet. · Abschnitt 4.5 · PDF-Seite 5

HOS-115731 · Präparat HOS-094345

Potentially fatal pancreatitis and hepatotoxicity, and severe peripheral neuropathy have been reported in HIV-infected patients who received hydroxycarbamide in combination with first generation antiretroviral medicinal products, particularly didanosine plus stavudine. Patients treated with hydroxycarbamide in combination with didanosine, stavudine, and indinavir showed a median decline in CD4 cells of approximately 100/mm3.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) stavudine (HOS-088080) didanosine (HOS-085836)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-19T17:00:00Z · SHA-256 1e4bd727405c22a6b3f38bab359ff4c6a64b14f17f97fda34f8bdbbb77504677 · Passage 486608d41800912a4e5dd0e7b62c915973a333e1eb536d7f8ff0820f40d09bd8 · Zeichen 77–505 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 11–12

HOS-116342 · Präparat HOS-094447

11 Raltegravir Some clinical studies suggest raltegravir At present the effect of raltegravir may cause a modest decrease in on darunavir plasma darunavir plasma concentrations. concentrations does not appear to be clinically relevant. Boosted PREZISTA and raltegravir can be used without dose adjustments. Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine didanosine AUC ↓ 9% Boosted PREZISTA and 400 mg once daily didanosine Cmin ND didanosine can be used without didanosine Cmax ↓ 16% dose adjustments. darunavir AUC ↔ Didanosine is to be administered darunavir Cmin ↔ on an empty stomach, thus it darunavir Cmax ↔ should be administered 1 hour before or 2 hours after boosted PREZISTA given with food. Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may 245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when boosted tenofovir Cmax ↑ 24% PREZISTA is given in # darunavir AUC ↑ 21% combination with tenofovir # darunavir Cmin ↑ 24% disoproxil, particularly in patients # with underlying systemic or renal darunavir Cmax ↑ 16% disease, or in patients taking (↑ tenofovir from effect on MDR-1 nephrotoxic agents. transport in the renal tubules) PREZISTA co-administered with cobicistat lowers the creatinine clearance. Refer to section 4.4 if creatinine clearance is used for dose adjustment of tenofovir disoproxil. Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with boosted PREZISTA. Abacavir Not studied. Based on the different Boosted PREZISTA can be used Emtricitabine elimination pathways of the other NRTIs with these NRTIs without dose Lamivudine zidovudine, emtricitabine, stavudine, adjustment. Stavudine lamivudine, that are primarily renally Zidovudine excreted, and abacavir for which PREZISTA co-administered with metabolism is not mediated by CYP450, cobicistat lowers the creatinine no interactions are expected for these clearance. Refer to section 4.4 if medicinal compounds and boosted creatinine clearance is used for PREZISTA. dose adjustment of emtricitabine or lamivudine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476) stavudine (HOS-088080) cobicistat (HOS-088111) creatinine (HOS-086273) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) raltegravir (HOS-086187) abacavir (HOS-088077) emtricitabine (HOS-085840)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 512d9066057a9fd93eb4b013c0f43af18ef8a6621ab7ae5b2a63872300e65b37 · Zeichen 8755–13360 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54

HOS-116511 · Präparat HOS-094447

53 Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine didanosine AUC ↓ 9% PREZISTA co-administered with 400 mg once daily didanosine Cmin ND low dose ritonavir and didanosine didanosine Cmax ↓ 16% can be used without dose darunavir AUC ↔ adjustments. darunavir Cmin ↔ Didanosine is to be administered darunavir Cmax ↔ on an empty stomach, thus it should be administered 1 hour before or 2 hours after PREZISTA/ritonavir given with food. Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may 245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when PREZISTA tenofovir Cmax ↑ 24% co-administered with low dose # darunavir AUC ↑ 21% ritonavir is given in combination # darunavir Cmin ↑ 24% with tenofovir disoproxil, # particularly in patients with darunavir Cmax ↑ 16% underlying systemic or renal (↑ tenofovir from effect on MDR-1 disease, or in patients taking transport in the renal tubules) nephrotoxic agents. Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with PREZISTA with low dose ritonavir. Abacavir Not studied. Based on the different PREZISTA co-administered with Emtricitabine elimination pathways of the other NRTIs low dose ritonavir can be used Lamivudine zidovudine, emtricitabine, stavudine, with these NRTIs without dose Stavudine lamivudine, that are primarily renally adjustment. Zidovudine excreted, and abacavir for which metabolism is not mediated by CYP450, no interactions are expected for these medicinal compounds and PREZISTA co-administered with low dose ritonavir. Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs) Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central 600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated efavirenz Cmax ↑ 15% with increased exposure to # darunavir AUC ↓ 13% efavirenz may be indicated when # darunavir Cmin ↓ 31% PREZISTA co-administered with # low dose ritonavir is given in darunavir Cmax ↓ 15% combination with efavirenz. (↑ efavirenz from CYP3A inhibition) (↓ darunavir from CYP3A induction) Efavirenz in combination with PREZISTA/ritonavir 800/100 mg once daily may result in sub-optimal darunavir Cmin. If efavirenz is to be used in combination with PREZISTA/ritonavir, the PREZISTA/ritonavir 600/100 mg twice daily regimen should be used (see section 4.4). Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with 100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine etravirine Cmax ↓ 32% 200 mg twice daily can be used darunavir AUC ↑ 15% without dose adjustments. darunavir Cmin ↔ darunavir Cmax ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476) stavudine (HOS-088080) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) efavirenz (HOS-087947) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f8ead3f953777de3c19f091bf055bc5528212e16095144f2b7b3940946af839d · Zeichen 6411–12375 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 93

HOS-116602 · Präparat HOS-094447

INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal product Interaction Recommendations concerning examples by therapeutic Geometric mean change (%) co-administration area HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir dolutegravir AUC ↓ 22% Boosted PREZISTA and dolutegravir C24h ↓ 38% dolutegravir can be used without dolutegravir Cmax ↓ 11% dose adjustment. darunavir ↔* * Using cross-study comparisons to historical pharmacokinetic data Raltegravir Some clinical studies suggest raltegravir At present the effect of raltegravir may cause a modest decrease in on darunavir plasma darunavir plasma concentrations. concentrations does not appear to be clinically relevant. Boosted PREZISTA and raltegravir can be used without dose adjustments. Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine didanosine AUC ↓ 9% Boosted PREZISTA and 400 mg once daily didanosine Cmin ND didanosine can be used without didanosine Cmax ↓ 16% dose adjustments. darunavir AUC ↔ Didanosine is to be administered darunavir Cmin ↔ on an empty stomach, thus it darunavir Cmax ↔ should be administered 1 hour before or 2 hours after boosted PREZISTA given with food.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dolutegravir (HOS-089992) didanosine (HOS-085836) raltegravir (HOS-086187)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 585aa838af78d412bb92c3071362c4c9c0001259848f355bfd7dbaf40f91a7bf · Zeichen 7993–10312 im Abschnitt

Wechselwirkungen · Intelence

INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-119733 · Präparat HOS-095005

Table 2: Interactions and dose recommendations with other medicinal products Medicinal products by Effects on drug levels Recommendations therapeutic areas Least Squares Mean Ratio concerning (90% CI; 1.00 = No effect) co-administration ANTI-INFECTIVES Antiretrovirals NRTIs Didanosine didanosine No significant effect on 400 mg once daily AUC ↔ 0.99 (0.79-1.25) didanosine and etravirine PK Cmin ND parameters is seen. Cmax ↔ 0.91 (0.58-1.42) INTELENCE and didanosine etravirine can be used without dose AUC ↔ 1.11 (0.99-1.25) adjustments. Cmin ↔ 1.05 (0.93-1.18) Cmax ↔ 1.16 (1.02-1.32) Tenofovir disoproxil tenofovir No significant effect on 245 mg once dailyb AUC ↔ 1.15 (1.09-1.21) tenofovir and etravirine PK Cmin ↑ 1.19 (1.13-1.26) parameters is seen. Cmax ↑ 1.15 (1.04-1.27) INTELENCE and tenofovir etravirine can be used without dose AUC ↓ 0.81 (0.75-0.88) adjustments. Cmin ↓ 0.82 (0.73-0.91) Cmax ↓ 0.81 (0.75-0.88) Other NRTIs Not studied, but no interaction expected based INTELENCE can be used on the primary renal elimination route for other with these NRTIs without NRTIs (e.g., abacavir, emtricitabine, dose adjustment. lamivudine, stavudine and zidovudine).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) stavudine (HOS-088080) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) abacavir (HOS-088077) emtricitabine (HOS-085840)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage f29152615b96440b7358c56a91ccfc38d2ce96481ae99b250502680fed6f7a18 · Zeichen 1742–3928 im Abschnitt

Wechselwirkungen · Lamivudine Teva Pharma B.V.

Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Lamivudine Teva Pharma B.V. 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-211903 · Präparat HOS-154784

The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when the main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine. The nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are unlikely to interact with lamivudine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) cimetidine (HOS-085835) didanosine (HOS-085836) zidovudine (HOS-085837) ranitidine (HOS-085660)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2023-04-21T15:48:00Z · SHA-256 20f7e52b86e41eb238a7c02628d41f826d204c97eddc200b9de9d5dfd73ec34c · Passage f95f33741513a03415ee49d3475d877bb6b9081af94776eebfc6141682077199 · Zeichen 793–1329 im Abschnitt

Quellenpassagen (53)

Wechselwirkungen · Viread

Wechselwirkungen · Viread

Wechselwirkungen · Reyataz

Wechselwirkungen · Reyataz

Wechselwirkungen · Reyataz

Wechselwirkungen · Reyataz

Wechselwirkungen · Reyataz

Wechselwirkungen · Reyataz

Wechselwirkungen · Reyataz

Wechselwirkungen · Reyataz

Wechselwirkungen · Kivexa

Wechselwirkungen · Truvada

Wechselwirkungen · Truvada

Wechselwirkungen · Aptivus

Wechselwirkungen · Siklos

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Intelence

Wechselwirkungen · Lamivudine Teva Pharma B.V.